BST Trade Alert
BST Trade Alert – April 24, 2015
Recommendation: Buy POZEN ($NASD: POZN) up to $9.00 per share. About the Company: POZEN calls themselves a ‘progressive pharmaceutical company’. They develop products to address unmet medical needs. They primarily develop drugs to treat pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Many of POZN’s developments combine aspirin with […]
BST Trade Alert – April 9, 2015
Recommendation: Buy Verastem $NASD: VSTM up to $12.00 per share. About the Company: Verastem is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling […]
BST Trade Alert – March 26, 2015
Recommendation: Buy Keryx Biopharmaceuticals $NASD: KERX up to $14.00 per share. About the Company: Keryx is a biopharmaceutical company focused on innovative therapies for the treatment of renal disease. Their product, Auryxia (ferric citrate), received marketing approval from the FDA in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, […]
BST Trade Alert – March 13, 2015
Recommendation: Buy Kamada $KMDA up to $5.00 per share. About the Company: Kamada became the first publicly traded biopharmaceutical company based in Israel back in 2005. They specialize in plasma-derived protein therapeutics with a focus on developing specialized treatments and developing strategic partnerships. The company has done a great job of developing partnerships and generating cash […]
BST Trade Alert – February 24, 2015
Recommendation: Buy Neuralstem (AMEX: CUR) up to $4.00 per share. About the Company: Neuralstem is a clinical stage biopharmaceutical company. They focus on the development and commercialization of treatments for central nervous system diseases. Their technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous […]
BST Trade Alert – January 29, 2015
Recommendation: Buy Dyax (NASDAQ: DYAX) up to $16.50 per share. About the Company: DYAX is a biopharmaceutical company that develops drugs to treat Hereditary Angioedema (HAE) and Other Plasma-Kallikrein-Mediated Disorders. And we believe DYAX has enormous potential. They have one product, ecallantide, that’s already approved by the FDA for treatment of HAE in patients 12 years […]
BST Trade Alert: December 4, 2014
Recommendation: Buy AcelRx Pharmaceuticals (NASDAQ: ACRX) up to $7.25 per share. About the Company: ACRX is the kind of biotech stock we love. They have a late-stage product candidate with blockbuster sales potential. Here’s why we’re very excited about ACRX… AcelRx is a specialty pharmaceutical focused on developing innovative therapies for acute and breakthrough pain. They currently […]
BST Trade Alert: October 17, 2014
October 17, 2014 Recommendation: Buy Arena Pharmaceuticals (NASDAQ: ARNA) up to $5.00 About the Company: Arena Pharmaceuticals brings innovative medicines targeting G protein-coupled receptors to patients. They launched their first approved drug, BELVIQ ® (lorcaserin HCl), in 2013. Arena is focused on discovering, developing, and commercializing additional drugs to address unmet medical needs. The company has an […]
BST Trade Alert: September 19, 2014
September 19, 2014 Recommendation: Buy Argos Therapeutics (NASDAQ: ARGS) up to $10.00 About the Company: Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. The company has two drugs in development that are expected to reach key […]
BST Trade Alert: August 14, 2014
August 14, 2014 Recommendation: Buy Aeterna Zentaris (NASDAQ: AEZS) up to $1.30 About the Company: Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology based in Quebec City, Canada. The Company’s pipeline encompasses compounds at various stages of development: Macrilen (macimorelin) – an orally-administered drug for the evaluation […]
